Denali Therapeutics (4DN) Price & Analysis

Compare

7 Followers

4DN Stock Chart & Stats

€15.90

€2.53(14.09%)

At close: Jan 08 4:00 PM EST

€15.90

€2.53(14.09%)

Day’s Range― - ―

52-Week Range€10.17 - €22.95

Previous CloseN/A

Volume0.00

Average Volume (3M)293.00

Market Cap

€2.23B

Enterprise Value€2.46B

Total Cash (Recent Filing)€848.20M

Total Debt (Recent Filing)€44.40M

Price to Earnings (P/E)―

Beta1.02

Next Earnings

Mar 02, 2026

EPS Estimate

-0.64

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.63

Shares Outstanding156,158,370

10 Day Avg. Volume139

30 Day Avg. Volume293

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)2.73

Price to Sales (P/S)0.00

P/FCF Ratio-9.22

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€26.64

Price Target Upside67.54% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PositionDNLI ended the third quarter with a strong cash position of $872.9 million, supporting ongoing and future developments.

Pipeline ExpansionThe company continues to execute on expanding its clinical pipeline, achieving its target of bringing two preclinical assets forward in 2025, with an additional one to two targeted annually moving forward.

Regulatory DevelopmentsDenali Therapeutics is experiencing positive regulatory developments that support its lead program, tividenofusp alfa, which has the potential to become a commercially disruptive program for Hunter's disease patients.

Bears Say

Leadership ChangesThe departure of Chief Medical Officer Carole Ho may be seen as a negative factor, although Dr. Peter Chin has been named Acting CMO and Head of Development.

Market PerformanceDenali shares are trading down around 30% year-to-date despite line of sight to becoming a commercial entity with tivi and progression of the platform for enhanced delivery of therapeutics to the brain.

Regulatory ChallengesThe recent delay in the 310 regulatory process resulted in a new PDUFA date of April 5th.

Denali Therapeutics News

Denali Therapeutics price target lowered to $30 from $31 at Wedbush

Wedbush analyst Laura Chico lowered the firm’s price target on Denali Therapeutics (DNLI) to $30 from $31 and...

13d ago

DNLI

Denali Therapeutics 9.143M share Spot Secondary priced at $17.50

The deal range was $17.00-$18.00. Goldman Sachs, JPMorgan, Morgan Stanley and Jefferies acted as joint book running managers...

14d ago

DNLI

Closing Bell Movers: GE Vernova up 6% on raised outlook, doubled dividend

In the opening hour of the evening session, U.S. equity futures are marginally lower, with S&P e-minis slipping...

14d ago

GEV

GME

Denali Therapeutics TBA Spot Secondary; price range $17.00-$18.00

Goldman Sachs, JPMorgan, Morgan Stanley and Jefferies are acting as joint book running managers for the offering. Published...

14d ago

DNLI

Denali Therapeutics offers to sell $200M in common stock

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Jefferies LLC are...

14d ago

DNLI

Denali Therapeutics price target raised to $29 from $26 at BofA

BofA raised the firm’s price target on Denali Therapeutics (DNLI) to $29 from $26 and keeps a Buy...

19d ago

DNLI

Denali Therapeutics price target raised to $31 from $30 at Wedbush

Wedbush analyst Laura Chico raised the firm’s price target on Denali Therapeutics (DNLI) to $31 from $30 and...

19d ago

DNLI

Royalty Pharma, Denali Therapeutics enter $275M royalty funding agreement

Royalty Pharma (RPRX) and Denali Therapeutics (DNLI) announced a $275M synthetic royalty funding agreement based on future net...

20d ago

DNLI

RPRX

Denali Therapeutics, Royalty Pharma announce $275M royalty funding agreement

Denali Therapeutics (DNLI) and Royalty Pharma (RPRX) announced a $275 million synthetic royalty funding agreement based on future...

20d ago

DNLI

RPRX

Denali Therapeutics Announces $200M Public Offering

Denali Therapeutics ( ($DNLI) ) has shared an update. On December 9, 2025, Denali Therapeutics entered into an...

13d ago

DNLI

Denali Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating

William Blair analyst Myles Minter has reiterated their bullish stance on DNLI stock, giving a Buy rating yesterday....

19d ago

DNLI

Denali Therapeutics: Promising Future with Strategic Agreements and Innovative Programs

Analyst Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics and keeping the price target at...

19d ago

DNLI

Denali Therapeutics Secures $275M Royalty Funding Deal

Denali Therapeutics ( ($DNLI) ) has issued an update. On December 4, 2025, Denali Therapeutics entered into a...

20d ago

DNLI

Denali Therapeutics Hosts Investor Day, Updates Pipeline

Denali Therapeutics ( ($DNLI) ) just unveiled an announcement. On December 4, 2025, Denali Therapeutics held its Investor...

20d ago

DNLI

4DN FAQ

What was Denali Therapeutics’s price range in the past 12 months?

Denali Therapeutics lowest stock price was €10.17 and its highest was €22.95 in the past 12 months.

What is Denali Therapeutics’s market cap?

Denali Therapeutics’s market cap is €2.23B.

When is Denali Therapeutics’s upcoming earnings report date?

Denali Therapeutics’s upcoming earnings report date is Mar 02, 2026 which is in 68 days.

How were Denali Therapeutics’s earnings last quarter?

Denali Therapeutics released its earnings results on Nov 06, 2025. The company reported -€0.632 earnings per share for the quarter, beating the consensus estimate of -€0.639 by €0.007.

Is Denali Therapeutics overvalued?

According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Denali Therapeutics pay dividends?

Denali Therapeutics does not currently pay dividends.

What is Denali Therapeutics’s EPS estimate?

Denali Therapeutics’s EPS estimate is -0.64.

How many shares outstanding does Denali Therapeutics have?

Denali Therapeutics has 156,158,370 shares outstanding.

What happened to Denali Therapeutics’s price movement after its last earnings report?

Denali Therapeutics reported an EPS of -€0.632 in its last earnings report, beating expectations of -€0.639. Following the earnings report the stock price went down -3.158%.

Which hedge fund is a major shareholder of Denali Therapeutics?

Currently, no hedge funds are holding shares in DE:4DN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Denali Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-39.69%

Trailing 12-Months

Asset Growth

-22.38%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Denali Therapeutics

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Denali Therapeutics (4DN) Earnings & Revenues

Historic Earnings Reports

4DN Stock 12 Month Forecast

Average Price Target

€26.64

▲(67.54% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"€10","21":"€21","32":"€32","15.5":"€15.5","26.5":"€26.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31.79519076,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€31.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.63921388,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€26.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.34256648,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€22.34</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,15.5,21,26.5,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.9,17.12270698153846,18.345413963076922,19.568120944615384,20.790827926153845,22.013534907692307,23.23624188923077,24.45894887076923,25.681655852307692,26.904362833846154,28.127069815384615,29.349776796923077,30.57248377846154,{"y":31.79519076,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.9,16.726093375384615,17.55218675076923,18.378280126153847,19.204373501538463,20.03046687692308,20.856560252307695,21.682653627692307,22.508747003076923,23.33484037846154,24.16093375384615,24.987027129230768,25.813120504615384,{"y":26.63921388,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.9,16.395582036923077,16.891164073846156,17.38674611076923,17.882328147692306,18.377910184615384,18.873492221538463,19.369074258461538,19.864656295384613,20.36023833230769,20.85582036923077,21.351402406153845,21.84698444307692,{"y":22.34256648,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.59,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.605,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.39,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.515,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.945,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.23,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.115,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >